MedTrace Logo

Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )

NCT07390604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2026-02-05

No results posted yet for this study

Summary

Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (\>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.

Conditions

  • Lipoprotein(a)
  • Lipoprotein-apheresis
  • Double-filtration Plasmapheresis
  • Hemodialysis Complication
  • End Stage Chronic Renal Failure

Sponsors & Collaborators

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Zead TUBAIL, MD · CHR Metz-Thionville Hopital de Mercy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07390604 on ClinicalTrials.gov